Enveric Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.4M
- Price
- $1.43
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.88%
- Volume
- 89.2K
About
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Quick stats
Shares outstanding4.0M
Computed float3.6M
Float / shares90.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000890821
Websitehttps://www.enveric.com
AI Summary
AI-generated1/35
minorneutralearnings
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Enveric Biosciences reported a Q2 net loss of $3.0 million, or $0.76 per share, narrowing from a loss of $11.65 per share in the prior-year quarter.
The company ended the quarter with $8.3 million in cash after raising $5.0 million in gross proceeds from a private placement and $1.5 million from warrant exercises.
Operationally, Enveric advanced IND-enabling studies for its lead asset EB-003 and received a Notice of Allowance for a patent covering its EVM401 Series.
Red flags
- Cash position of $8.3M is low given ongoing preclinical and planned clinical development activities
- Warrants are at-the-market, posing dilution risk